Boost for Basilea as isavuconazole meets Phase III endpoint
This article was originally published in Scrip
Basilea Pharmaceutica and global co-development partner Astellas have reached what they see as a critical milestone in the development of their broad-spectrum antifungal isavuconazole, which has demonstrated non-inferiority to voriconazole in a Phase III trial for invasive aspergillosis.
You may also be interested in...
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.